|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Sagaert X, Topal B,
Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kanat O and O'Neil BH: Metastatic gastric
cancer treatment: A little slow but worthy progress. Med Oncol.
30:4642013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ohtsu A: Chemotherapy for metastatic
gastric cancer: Past, present, and future. J Gastroenterol.
43:256–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al MAGIC Trial Participants: Perioperative
chemotherapy versus surgery alone for resectable gastroesophageal
cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee JH, Kim KM, Cheong JH and Noh SH:
Current management and future strategies of gastric cancer. Yonsei
Med J. 53:248–257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Madsen P, Rasmussen HH, Leffers H, Honoré
B, Dejgaard K, Olsen E, Kiil J, Walbum E, Andersen AH, Basse B, et
al: Molecular cloning, occurrence, and expression of a novel
partially secreted protein 'psoriasin' that is highly up-regulated
in psoriatic skin. J Invest Dermatol. 97:701–712. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Watson PH, Leygue ER and Murphy LC:
Psoriasin (S100A7). Int J Biochem Cell Biol. 30:567–571. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jinquan T, Vorum H, Larsen CG, Madsen P,
Rasmussen HH, Gesser B, Etzerodt M, Honoré B, Celis JE and
Thestrup-Pedersen K: Psoriasin: A novel chemotactic protein. J
Invest Dermatol. 107:5–10. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Enerbäck C, Porter DA, Seth P, Sgroi D,
Gaudet J, Weremowicz S, Morton CC, Schnitt S, Pitts RL, Stampl J,
et al: Psoriasin expression in mammary epithelial cells in vitro
and in vivo. Cancer Res. 62:43–47. 2002.PubMed/NCBI
|
|
11
|
Zhou G, Xie TX, Zhao M, Jasser SA, Younes
MN, Sano D, Lin J, Kupferman ME, Santillan AA, Patel V, et al:
Reciprocal negative regulation between S100A7/psoriasin and
beta-catenin signaling plays an important role in tumor progression
of squamous cell carcinoma of oral cavity. Oncogene. 27:3527–3538.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deol YS, Nasser MW, Yu L, Zou X and Ganju
RK: Tumor-suppressive effects of psoriasin (S100A7) are mediated
through the β-catenin/T cell factor 4 protein pathway in estrogen
receptor-positive breast cancer cells. J Biol Chem.
286:44845–44854. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H, Zhao Q, Chen Y, Wang Y, Gao S,
Mao Y, Li M, Peng A, He D and Xiao X: Selective expression of
S100A7 in lung squamous cell carcinomas and large cell carcinomas
but not in adenocarcinomas and small cell carcinomas. Thorax.
63:352–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang L, Wu RL and Xu AM:
Epithelial-mesenchymal transition in gastric cancer. Am J Transl
Res. 7:2141–2158. 2015.
|
|
15
|
Moubayed N, Weichenthal M, Harder J,
Wandel E, Sticherling M and Gläser R: Psoriasin (S100A7) is
significantly up-regulated in human epithelial skin tumours. J
Cancer Res Clin Oncol. 133:253–261. 2007. View Article : Google Scholar
|
|
16
|
Tripathi SC, Matta A, Kaur J, Grigull J,
Chauhan SS, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R,
et al: Nuclear S100A7 is associated with poor prognosis in head and
neck cancer. PLoS One. 5:e119392010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye L, Sun PH, Martin TA, Sanders AJ, Mason
MD and Jiang WG: Psoriasin (S100A7) is a positive regulator of
survival and invasion of prostate cancer cells. Urol Oncol.
31:1576–1583. 2013. View Article : Google Scholar
|
|
18
|
Tian T, Li X, Hua Z, Ma J, Wu X, Liu Z,
Chen H and Cui Z: S100A7 promotes the migration, invasion and
metastasis of human cervical cancer cells through
epithelial-mesenchymal transition. Oncotarget. 8:24964–24977.
2017.PubMed/NCBI
|
|
19
|
Nasser MW, Wani NA, Ahirwar DK, Powell CA,
Ravi J, Elbaz M, Zhao H, Padilla L, Zhang X, Shilo K, et al: RAGE
mediates S100A7-induced breast cancer growth and metastasis by
modulating the tumor microenvironment. Cancer Res. 75:974–985.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Emberley ED, Niu Y, Curtis L, Troup S,
Mandal SK, Myers JN, Gibson SB, Murphy LC and Watson PH: The
S100A7-c-Jun activation domain binding protein 1 pathway enhances
prosurvival pathways in breast cancer. Cancer Res. 65:5696–5702.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Keese CR, Wegener J, Walker SR and Giaever
I: Electrical wound-healing assay for cells in vitro. Proc Natl
Acad Sci USA. 101:1554–1559. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Szulcek R, Bogaard HJ and van Nieuw
Amerongen GP: Electric cell-substrate impedance sensing for the
quantification of endothelial proliferation, barrier function, and
motility. Journal of visualized experiments J Vis Exp.
85:513002014.
|
|
24
|
Wegener J, Keese CR and Giaever I:
Electric cell-substrate impedance sensing (ECIS) as a noninvasive
means to monitor the kinetics of cell spreading to artificial
surfaces. Exp Cell Res. 259:158–166. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Keates S, Sougioultzis S, Keates AC, Zhao
D, Peek RM Jr, Shaw LM and Kelly CP: cag+ Helicobacter pylori
induce transactivation of the epidermal growth factor receptor in
AGS gastric epithelial cells. J Biol Chem. 276:48127–48134. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akagi T and Kimoto T: Human cell line
(HGC-27) derived from the metastatic lymph node of gastric cancer.
Acta Med Okayama. 30:215–219. 1976.PubMed/NCBI
|
|
27
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chambard JC, Lefloch R, Pouysségur J and
Lenormand P: ERK implication in cell cycle regulation. Biochim
Biophys Acta. 1773:1299–1310. 2007. View Article : Google Scholar
|
|
29
|
Jiang WG, Watkins G, Douglas-Jones A and
Mansel RE: Psoriasin is aberrantly expressed in human breast cancer
and is related to clinical outcomes. Int J Oncol. 25:81–85.
2004.PubMed/NCBI
|
|
30
|
Liu Y, Bunston C, Hodson N, Resaul J, Sun
PH, Cai S, Chen G, Gu Y, Satherley LK, Bosanquet DC, et al:
Psoriasin promotes invasion, aggregation and survival of pancreatic
cancer cells; association with disease progression. Int J Oncol.
50:1491–1500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kalluri R and Neilson EG:
Epithelial-mesenchymal transition and its implications for
fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Son H and Moon A: Epithelial-mesenchymal
transition and cell invasion. Toxicol Res. 26:245–252. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Scanlon CS, Van Tubergen EA, Inglehart RC
and D'Silva NJ: Biomarkers of epithelial-mesenchymal transition in
squamous cell carcinoma. J Dent Res. 92:114–121. 2013. View Article : Google Scholar :
|
|
34
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar
|
|
35
|
Steelman LS, Chappell WH, Abrams SL, Kempf
RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F,
Mazzarino MC, et al: Roles of the Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging (Albany NY).
3:192–222. 2011. View Article : Google Scholar
|
|
36
|
Abrams SL, Steelman LS, Shelton JG, Wong
EW, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra
M, et al: The Raf/MEK/ERK pathway can govern drug resistance,
apoptosis and sensitivity to targeted therapy. Cell Cycle.
9:1781–1791. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shiota M, Tsunoda T, Song Y, Yokomizo A,
Tada Y, Oda Y and Naito S: Enhanced S100 calcium-binding protein P
expression sensitizes human bladder cancer cells to cisplatin. BJU
Int. 107:1148–1153. 2011. View Article : Google Scholar
|
|
38
|
Acharyya S, Oskarsson T, Vanharanta S,
Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N,
Seshan VE, et al: A CXCL1 paracrine network links cancer
chemoresistance and metastasis. Cell. 150:165–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Arumugam T, Ramachandran V, Sun D, Peng Z,
Pal A, Maxwell DS, Bornmann WG and Logsdon CD: Designing and
developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer
therapy. Mol Cancer Ther. 12:654–662. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zagryazhskaya A, Surova O, Akbar NS,
Allavena G, Gyuraszova K, Zborovskaya IB, Tchevkina EM and
Zhivotovsky B: Tudor staphylococcal nuclease drives
chemo-resistance of non-small cell lung carcinoma cells by
regulating S100A11. Oncotarget. 6:12156–12173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dai Z, Huang Y and Sadée W: Growth factor
signaling and resistance to cancer chemotherapy. Curr Top Med Chem.
4:1347–1356. 2004. View Article : Google Scholar : PubMed/NCBI
|
